Multiple sclerosis : tissue destruction and repair PDF
Preview Multiple sclerosis : tissue destruction and repair
Multiple Sclerosis: Tissue Destruction and Repair MULTIPLE SCLEROSIS TISSUE DESTRUCTION AND REPAIR Edited by LUDWIG KAPPOS MD Professor of Neurology/Clinical Neuroimmunology Head of Outpatient Clinics Neurology and Neurosurgery University Hospitals Kantonsspital Basel Switzerland JÜRG KESSELRING MD Professor of Neurology and Neurorehabilitation University of Bern and Zürich Head of Neurology Klinik Valens Switzerland ERNST W RADÜ MD Professor of Neuroradiology Head of Neuroradiology University Hospitals Kantonsspital Basel Switzerland KENNETH JOHNSON MD Professor and Chair Department of Neurology School of Medicine University of Maryland Baltimore MD USA Published in association with the American and the European Committees for Treatment and Reseach in Multiple Sclerosis (ACTRIMS and ECTRIMS) MARTIN DUNITZ Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publishers nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. For detailed prescribing information or instructions on the use of any product or procedure discussed herein, please consult the prescribing information or instructional material issued by the manufacturer. © 2001 Martin Dunitz Ltd, a member of the Taylor & Francis group First published in the United Kingdom in 2001 by Martin Dunitz Ltd, The Livery House, 7–9 Pratt Street, London NW1 0AE Tel: +44 (0) 20 7482 2202 Fax: +44 (0) 20 7267 0159 E-mail: [email protected] Website: http://www.dunitz.co.uk This edition published in the Taylor & Francis e-Library, 2005. To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. A CIP record for this book is available from the British Library. ISBN 0-203-21297-5 Master e-book ISBN ISBN 0-203-29116-6 (Adobe e-Reader Format) ISBN 1 85317 872 1 (Print Edition) Distributed in the USA by Fulfilment Center Taylor & Francis 7625 Empire Drive Florence, KY 41042, USA Toll Free Tel.: +1 800 634 7064 E-mail: cserve@routledge_ny.com Distributed in Canada by Taylor & Francis 74 Rolark Drive Scarborough, Ontario M1R 4G2, Canada Toll Free Tel.: +1 877 226 2237 E-mail: [email protected] Distributed in the rest of the world by ITPS Limited Cheriton House North Way, Andover, Hampshire SP10 5BE, UK Tel.: +44 (0)1264 332424 E-mail: [email protected] Composition by Wearset, Boldon, Tyne and Wear Contents Contributors xii Preface xxvi I CNS-tissue-immune interactions 1. Neuronal control of the immune response in the CNS: implications on 3 neuronal cell death and survival Harald Neumann 2. Oligodendrocyte susceptibility to immune-mediated injury 12 Jack Antel 3. Strategies for repair in MS: the potential role of glial-cell transplantation 28 Ian D Duncan 4. Growth factors, lesion repair and myelin regeneration 38 Henry deF Webster 5. Effects of BDNF and NGF on cytokine expression in immune cells 48 Antonios Bayas , Niels Kruse , Neville F Moriabadi , Klaus Viktor Toyka and Peter Rieckmann II In vivo assessment of tissue destruction and its consequences Imaging 6. Magnetization transfer imaging in multiple sclerosis 55 Massimo Filippi , Joseph C McGowan and Carla Tortorella 7. Clinicopathological correlations for black holes: an MRI marker for axonal 79 loss? Peter Freitag and Frederik Barkhof 8. Magnetic resonance spectroscopy of multiple sclerosis: imaging axonal 90 damage Douglas L Arnold , Sridar Narayanan , Nicola De Stefano , Hasini Reddy and Paul M Matthews 9. Measurement of atrophy 107 Elizabeth Fisher and Richard A Rudick 10. Quantification of MS lesion evolution in a serial MRI study 116 Guido Gerig , Daniel Welti , Gábor Székely , Ernst W Radü and Ludwig Kappos 11. Functional imaging 133 Isabelle Berry , Danielle Ibarrola , Jean-Philippe Ranjeva , Claude Mekiès , Kader Boulanouar , Claude Manelfe and Michel Clanet 12. A 1-year serial clinical and MRI study of primary progressive multiple 142 sclerosis Valerie L Stevenson , David H Miller , Marco Rovaris , Frederik Barkhof , Bruno Brochet , Massimo Filippi , Xavier Montalban Gairin , Chris H Polman , Alex Rovira , Joa de Sa and Alan J Thompson II In vivo assessment of tissue destruction and its consequences Body fluid markers and neurophysiology 13. Immunological parameters in blood as surrogate markers in multiple sclerosis 152 Bernd C Kieseier , Juan J Archelos , Gavin Giovannoni and Hans-Peter Hartung 14. Cerebrospinal fluid markers of tissue destruction and repair in multiple 172 sclerosis Gavin Giovannoni , Alison JE Green and Edward J Thompson 15. Myelin products: myelin basic protein like material in cerebrospinal fluid and 184 urine in multiple sclerosis John N Whitaker , Lori U Coward , Marion C Kirk , Patricia Jackson and Ligong Cao 16. In vivo assessment of tissue destruction and repair: the role of 194 neurophysiology Peter Fuhr III MS fatigue 17. Pathophysiology of fatigue in multiple sclerosis 203 Ulrich Roelcke 18. Assessment and treatment of fatigue in multiple sclerosis 210 Lauren B Krupp IV New immunologic concepts and their therapeutic consequences 19. T-cell autoreactivity against self glycosphingolipids in multiple sclerosis 222 Gennaro De Libero , Abdijapar Shamshiev , Alena Donda , Vania Manolova , Hans Jürgen Gober , Alessandra Sacchi , Lucia Mori and Ludwig Kappos 20. Degeneracy in T-cell antigen recognition 234 Bernhard Hemmer and Norbert Sommer 21. T-cell apoptosis in the nervous system and therapeutic implications 252 Ralf Gold , Klaus Viktor Toyka and Hans Lassmann 22. IL-12: immunological staging of multiple sclerosis and measure of response to 259 therapy Karim Makhlouf , Samia J Khoury and Howard L Weiner 23. Interferon-β-1b inhibits interleukin-12 production in peripheral blood 267 mononuclear cells through an interleukin-10 dependent mechanism Suhayl Dhib-Jalbut and Xin Wang 24. T-cell vaccination and antigen-driven immunotherapy for multiple sclerosis 277 Ariel Miller and Jingwu Zhang 25. Specific immunomodulation in multiple sclerosis by altered peptide ligands 291 Roland Martin V Treatment of relapses 26. Treatment of relapses: update on steroids, mode of action, optimal route and 305 dosage Xavier Montalban Gairin and Carlos Nos 27. Plasma exchange for severe attacks of demyelinating disease of the central 316 nervous system Brian G Weinshenker VI Modern concepts of therapeutic immunosuppression 28. Intensive immunosuppression in multiple sclerosis: efficacy versus toxicity 328 Richard E Gonsette 29. The role of intensive immunosuppression in multiple sclerosis: prospects of 339 combinations Gilles Edan and the Mitoxantrone-Interferon-β-1b European Multicenter Trial Group 30. High-dose immunosuppression and peripheral stem cell transplantation in 346 multiple sclerosis: preclinical experience and problems Dimitrios M Karussis 31. Autologous stem cell transplantation in multiple sclerosis: preliminary clinical 358 results and future activities Giancarlo Comi , Gianvito Martino and the BMT-MS Study Group VII Update on therapeutic trials 32. Improvement of magnetization transfer ratio in new gadolinium-enhanced 370 lesions detected before and during therapy with interferon-β-1a Mariko Kita , Donald E Goodkin , Peter Bacchetti , Emmanuelle Waubant , Sarah J Nelson and Sharmila Majumdar 33. Longitudinal prospective evaluation of treatment effects, MRI and neutralizing 377 antibodies in multiple sclerosis patients treated long-term with interferon-β-1b
The list of books you might like
